Loading stock data…
Seres Therapeutics, Inc. (MCRB)
$5.56-0.16 (-2.80%)
Market ClosedLast close Sep 8
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Seres Therapeutics, Inc. in the Healthcare sector is trading at $5.56 with a market capitalization of $46M. Wall Street consensus targets $17.00 (2 analysts), implying a +205.8% move over the next 12 months. The stock is currently near its 52-week low of $4.32, remaining 42.4% below its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 73 is overbought against a weak tape. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +205.8% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Overbought RSI 73 against a weak tape — risk of pullback
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $736,000↑ | $358,000↓ | $789,000 | $0 | $0 |
| Gross Profit | $736,000↑ | $358,000↑ | $197,000↑ | -$736,000↑ | -$1.69M |
| Operating Income | -$15.47M↑ | -$20.91M↓ | -$19.38M↑ | -$22.48M↑ | -$24.88M |
| Net Income | $4.58M↑ | -$19.91M↓ | -$15.34M↓ | $8.20M↑ | -$19.86M |
Peer Comparison
JNJUNHPFE
Fundamentals
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integr...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$45.60M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.21
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-65.05%
Volume
Today's trading volume
36,633
Recent News
Seres Therapeutics’ SER-155 Posts 80% Response in Cancer Immunotherapy GI Toxicity Study
Seres Therapeutics (NASDAQ:MCRB) reported results from an investigator-sponsored study of SER-155 in immune checkpoint inhibitor-related enterocolitis, or irEC, saying the data support further evaluation of the live biotherapeutic as a potential non-immunosuppressive treatment option for cancer pati
We're A Little Worried About Seres Therapeutics' (NASDAQ:MCRB) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Seres Therapeutics: Q4 Earnings Snapshot
CAMBRIDGE, Mass. AP) — Seres Therapeutics Inc. MCRB) on Thursday reported a loss of $15.3 million in its fourth quarter.
Sector Update: Health Care Stocks Rise Late Afternoon
Health care stocks were higher late Thursday afternoon, with the NYSE Health Care Index adding 0.8%
Seres to lay off staff, pause top program in latest reboot
The microbiome specialist, which for years has struggled to stay afloat, is cutting its staff by 30% and focusing resources on earlier, immunology-focused research.